Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
TNAXPhase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026
August 13, 2025Earnings
Read more →